ADC Therapeutics pauses enrolment in mid-stage trial for cancer therapy

ADC Therapeutics SA

11/07/2023 12:17

July 11 (Reuters) - ADC Therapeutics  ADCT.N  said on
Tuesday it had paused enrollment of new patients in a mid-stage
study evaluating its drug Zynlonta along with rituximab for
treating a type of blood cancer over safety concerns. 

 (Reporting by Raghav Mahobe in Bengaluru; Editing by Sriraj
Kalluvila)
 ((Raghav.Mahobe@thomsonreuters.com;))